Payment overview · 2025
General Payments
$72.57
4 reported records · 4 companies
Healthcare provider profile · identity verified
John D Ledbetter, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1750355004
Verified facts
What the public records show
CMS Open Payments records show John D Ledbetter, D.O. received $72.57 in general payments during 2025 across 4 reported records.
Lilly USA, LLC accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.64 | 31.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.72 | 27.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.59 | 22.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.62 | 18.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $72.57 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 298 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
153 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
298 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
159 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 672 | 202 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 557 | 183 |
| Lisinopril | Lisinopril | 532 | 167 |
| Metformin Hcl | Metformin Hcl | 456 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 132 |
| Losartan Potassium | Losartan Potassium | 339 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 336 | 118 |
| Mounjaro | Tirzepatide | 298 | 56 |
| Omeprazole | Omeprazole | 268 | 88 |
| Tramadol Hcl | Tramadol Hcl | 234 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 218 | 76 |
| Fluticasone Propionate | Fluticasone Propionate | 208 | 93 |
| Gabapentin | Gabapentin | 208 | 74 |
| Alprazolam | Alprazolam | 204 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 62 |
| Lovastatin | Lovastatin | 176 | 55 |
| Carvedilol | Carvedilol | 162 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 51 |
| Alendronate Sodium | Alendronate Sodium | 160 | 63 |
| Trulicity | Dulaglutide | 159 | 30 |
| Jardiance | Empagliflozin | 153 | 38 |
| Furosemide | Furosemide | 147 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 45 |
| Montelukast Sodium | Montelukast Sodium | 123 | 43 |
| Glimepiride | Glimepiride | 122 | 45 |
| Famotidine | Famotidine | 108 | 55 |
| Simvastatin | Simvastatin | 108 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 21 |
| Ozempic | Semaglutide | 100 | 26 |
| Metformin Hcl Er | Metformin Hcl | 99 | 39 |
| Allopurinol | Allopurinol | 96 | 28 |
| Sertraline Hcl | Sertraline Hcl | 94 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 37 |
| Potassium Chloride | Potassium Chloride | 86 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 62 |
| Trazodone Hcl | Trazodone Hcl | 75 | 30 |
| Meloxicam | Meloxicam | 73 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 27 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 69 | 19 |
| Eliquis | Apixaban | 67 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 19 |
| Finasteride | Finasteride | 61 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 25 |
| Glipizide | Glipizide | 57 | 21 |
| Bupropion Xl | Bupropion Hcl | 55 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 24 |
| Ipratropium Bromide | Ipratropium Bromide | 55 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 45 |
| Celecoxib | Celecoxib | 50 | 21 |
| Prednisone | Prednisone | 50 | 36 |
| Atenolol | Atenolol | 49 | 18 |
| Farxiga | Dapagliflozin Propanediol | 48 | 14 |
| Lorazepam | Lorazepam | 46 | suppressed |
| Ramipril | Ramipril | 46 | 18 |
| Januvia | Sitagliptin Phosphate | 45 | 15 |
| Mirtazapine | Mirtazapine | 44 | 14 |
| Chlorthalidone | Chlorthalidone | 42 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 22 |
| Ezetimibe | Ezetimibe | 38 | 14 |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 19 |
| Myrbetriq | Mirabegron | 37 | 11 |
| Buspirone Hcl | Buspirone Hcl | 36 | 13 |
| Ibuprofen | Ibuprofen | 36 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Spironolactone | Spironolactone | 35 | 13 |
| Azithromycin | Azithromycin | 34 | 33 |
| Roflumilast | Roflumilast | 33 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Valsartan | Valsartan | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 21 |
| Ondansetron Odt | Ondansetron | 31 | 23 |
| Lactulose | Lactulose | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | 13 |
| Baclofen | Baclofen | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | 11 |
| Pregabalin | Pregabalin | 27 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 27 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Clotrimazole | Clotrimazole | 25 | 17 |
| Lidocaine | Lidocaine | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Naproxen | Naproxen | 24 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 15 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $72.57 · 4 records | Lilly USA, LLC | CAPVAXIVE, GARDASIL 9, Korlym, MOUNJARO, The Cologuard Plus Collection Kit | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error